The impact of antidepressant medications on the course of inflammatory bowel diseases
DOI:
https://doi.org/10.12775/JEHS.2024.67.55078Keywords
Selected:inflammatory bowel disease, depression, antidepressantsAbstract
Introduction and Objective: Inflammatory bowel diseases (IBD) and anxiety, as well as depressive disorders, can coexist. Depression may affect IBD symptoms and vice versa. The aim of our study is to determine the impact of different classes of antidepressant medications in the treatment of IBD with comorbid depressive episodes, to summarize the most commonly used therapies, and to identify the most effective practices in treating inflammatory diseases with coexisting depressive episodes.
Materials and Methods: A review of the available literature was conducted by searching the PubMed and Google Scholar databases using the following keywords: inflammatory bowel diseases, depression, antidepressants, in both English and Polish, up until July 19, 2024. To ensure the high quality of the narrative review, the SANRA scale (a scale for the quality assessment of narrative review articles) was used.
Results: Studies indicate that depressive symptoms occur in approximately 25-27.5% of patients with inflammatory bowel diseases (IBD). Treatment of depression in IBD patients often includes the use of antidepressant medications, such as selective serotonin reuptake inhibitors (SSRIs), which not only reduce depression but also exhibit anti-inflammatory effects. SSRIs may also be effective in improving patients' quality of life; however, they may cause side effects such as diarrhea and an increased risk of bleeding. In addition to SSRIs, other antidepressants, such as serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and atypical antipsychotics, are also used and may have a beneficial impact on the course of the disease.
Conclusions: In patients with IBD and comorbid depression, SSRIs are most commonly used, followed by TLPDs, SNRIs, and atypical antipsychotics. Drugs from these groups may have a beneficial effect on depressive symptoms, but also affect the course of IBD.
Further clinical studies are needed to establish precise guidelines for the use of these drugs in patients with IBD.
References
Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12(4):205–217. doi:10.1038/nrgastro.2015.34
Zhang YZ. Inflammatory bowel disease: Pathogenesis. World J Gastroenterol. 2014;20(1):91. doi:10.3748/wjg.v20.i1.91
Mikocka-Walus A, Ford AC, Drossman DA. Antidepressants in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(3):184–192. doi:10.1038/s41575-019-0259-y
Luo J, Xu Z, Noordam R, van Heemst D, Li-Gao R. Depression and Inflammatory Bowel Disease: A Bidirectional Two-sample Mendelian Randomization Study. J Crohn’s Colitis. 2022;16(4):633–642. doi:10.1093/ecco-jcc/jjab191
Frolkis AD, Vallerand IA, Shaheen AA, et al. Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression. Gut. 2019;68(9):1606–1612. doi:10.1136/gutjnl-2018-317182
Ananthakrishnan AN, Khalili H, Pan A, et al. Association Between Depressive Symptoms and Incidence of Crohn’s Disease and Ulcerative Colitis: Results From the Nurses’ Health Study. Clin Gastroenterol Hepatol. 2013;11(1):57–62. doi:10.1016/j.cgh.2012.08.032
Halfvarson J, Brislawn CJ, Lamendella R, et al. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat Microbiol. 2017;2(5):17004. doi:10.1038/nmicrobiol.2017.4
Franzosa EA, Sirota-Madi A, Avila-Pacheco J, et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol. 2018;4(2):293–305. doi:10.1038/s41564-018-0306-4
Osadchiy V, Martin CR, Mayer EA. The Gut–Brain Axis and the Microbiome: Mechanisms and Clinical Implications. Clin Gastroenterol Hepatol. 2019;17(2):322–332. doi:10.1016/j.cgh.2018.10.002
Bonaz BL, Bernstein CN. Brain-Gut Interactions in Inflammatory Bowel Disease. Gastroenterology. 2013;144(1):36–49. doi:10.1053/j.gastro.2012.10.003
Kostic AD, Xavier RJ, Gevers D. The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead. Gastroenterology. 2014;146(6):1489–1499. doi:10.1053/j.gastro.2014.02.009
Mayer EA, Savidge T, Shulman RJ. Brain–Gut Microbiome Interactions and Functional Bowel Disorders. Gastroenterology. 2014;146(6):1500–1512. doi:10.1053/j.gastro.2014.02.037
Graeff FG, Zangrossi H. The hypothalamic-pituitary-adrenal axis in anxiety and panic. Psychol Neurosci. 2010;3(1):3–8. doi:10.3922/j.psns.2010.1.002
Graff LA, Walker JR, Bernstein CN. Depression and anxiety in inflammatory bowel disease: A review of comorbidity and management. Inflammatory Bowel Diseases. 2009;15(7):1105–1118. doi:10.1002/ibd.20873
Miller AH, Maletic V, Raison CL. Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression. Biol Psychiatry. 2009;65(9):732–741. doi:10.1016/j.biopsych.2008.11.029
Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22–34. doi:10.1038/nri.2015.5
Sobin HW, Heinrich TW, Drossman DA. Central Neuromodulators for Treating Functional GI Disorders: A Primer. Am J Gastroenterol. 2017;112(5):693–702. doi:10.1038/ajg.2017.57
Dekel R, Drossman DA, Sperber AD. The use of psychotropic drugs in irritable bowel syndrome. Expert Opin Investig Drugs. 2013;22(3):329–339. doi:10.1517/13543784.2013.761205
Hall BJ, Hamlin PJ, Gracie DJ, Ford AC. The Effect of Antidepressants on the Course of Inflammatory Bowel Disease. Can J Gastroenterol Hepatol. 2018:1–11. doi:10.1155/2018/2047242
Cai Z, Wang S, Li J. Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Front Med. 2021;8. doi:10.3389/fmed.2021.765474
Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integrity Peer Rev. 2019;4:5. doi:10.1186/s41073-019-0064-8
Walker JR, Ediger JP, Graff LA, et al. The Manitoba IBD Cohort Study: A Population-Based Study of the Prevalence of Lifetime and 12-Month Anxiety and Mood Disorders. Am J Gastroenterol. 2008;103(8):1989–1997. doi:10.1111/j.1572-0241.2008.01980.x
Tarricone I, Regazzi MG, Bonucci G, et al. Prevalence and effectiveness of psychiatric treatments for patients with IBD: A systematic literature review. J Psychosom Res. 2017;101:68–95. doi:10.1016/j.jpsychores.2017.07.001
Hatamnejad MR, Baradaran Ghavami S, Shirvani M, et al. Selective serotonin reuptake inhibitors and inflammatory bowel disease; Beneficial or malpractice. Front Immunol. 2022;13. doi:10.3389/fimmu.2022.980189
Thorkelson G, Bielefeldt K, Szigethy E. Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD. Inflammatory Bowel Diseases. 2016;22(6):1509–1522. doi:10.1097/MIB.0000734
Jonnakuty C, Gragnoli C. What do we know about serotonin? J Cell Physiol. 2008;217(2):301–306. doi:10.1002/jcp.21533
O’Brien SM, Scott Lv, Dinan TG. Antidepressant therapy and C-reactive protein levels. Br J Psychiatry. 2006;188(5):449–452. doi:10.1192/bjp.bp.105.011015
Horikawa H, Kato TA, Mizoguchi Y, et al. Inhibitory effects of SSRIs on IFN-γ induced microglial activation through the regulation of intracellular calcium. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(7):1306–1316. doi:10.1016/j.pnpbp.2010.07.015
Hashioka S, Klegeris A, Monji A, et al. Antidepressants inhibit interferon-γ-induced microglial production of IL-6 and nitric oxide. Exp Neurol. 2007;206(1):33–42. doi:10.1016/j.expneurol.2007.03.022
Tynan RJ, Weidenhofer J, Hinwood M, et al. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun. 2012;26(3):469–479. doi:10.1016/j.bbi.2011.12.011
Zhu J, Smith K, Hsieh PN, et al. High-Throughput Screening for TLR3–IFN Regulatory Factor 3 Signaling Pathway Modulators Identifies Several Antipsychotic Drugs as TLR Inhibitors. J Immunol. 2010;184(10):5768–5776. doi:10.4049/jimmunol.0903559
Kristensen MS, Kjærulff TM, Ersbøll AK, et al. The Influence of Antidepressants on the Disease Course Among Patients With Crohn’s Disease and Ulcerative Colitis—A Danish Nationwide Register–Based Cohort Study. Inflamm Bowel Dis. 2019;25(5):886-893. doi:10.1093/ibd/izy367
de Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ. 1999;319(7217):1106-1109. doi:10.1136/bmj.319.7217.1106
Walsky RL, Astuccio AV, Obach RS. Evaluation of 227 Drugs for In Vitro Inhibition of Cytochrome P450 2B6. J Clin Pharmacol. 2006;46(12):1426-1438. doi:10.1177/0091270006293753
Ferguson JM. SSRI Antidepressant Medications. Prim Care Companion CNS Disord. 2001;3(1). doi:10.4088/PCC.v03n0105
Sussman N, Ginsberg D. Rethinking Side Effects of the Selective Serotonin Reuptake Inhibitors: Sexual Dysfunction and Weight Gain. Psychiatr Ann. 1998;28(2):89-97. doi:10.3928/0048-5713-19980201-10
Albenberg L, Esipova TV, Judge CP, et al. Correlation Between Intraluminal Oxygen Gradient and Radial Partitioning of Intestinal Microbiota. Gastroenterology. 2014;147(5):1055-1063.e8. doi:10.1053/j.gastro.2014.07.020
Cheng JY. Serotonin Reuptake Inhibitors in Obstructive Sleep Apnea: Associations in People with and without Epilepsy. Neurol Res Int. 2018;2018:7247605. doi:10.1155/2018/7247605
Srinath AI, Walter C, Newara MC, Szigethy EM. Pain management in patients with inflammatory bowel disease: insights for the clinician. Ther Adv Gastroenterol. 2012;5(5):339-357. doi:10.1177/1756283X12446158
Liang C, Chen P, Tang Y, et al. Venlafaxine as an Adjuvant Therapy for Inflammatory Bowel Disease Patients With Anxious and Depressive Symptoms: A Randomized Controlled Trial. Front Psychiatry. 2022;13. doi:10.3389/fpsyt.2022.880058
Daghzadeh H, Naji F, Afshar H, et al. Efficacy of duloxetine add on in treatment of inflammatory bowel disease patients: A double-blind controlled study. J Res Med Sci. 2015;20(6):595. doi:10.4103/1735-1995.165969
Baldwin DS, Papakostas GI. Symptoms of fatigue and sleepiness in major depressive disorder. J Clin Psychiatry. 2006;67 Suppl 6:9-15.
Bailey RK, Mallinckrodt CH, Wohlreich MM, Watkin JG, Plewes JM. Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy. J Natl Med Assoc. 2006;98(3):437-447.
Colombel JF, Shin A, Gibson PR. AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review. Clin Gastroenterol Hepatol. 2019;17(3):380-390.e1. doi:10.1016/j.cgh.2018.08.001
Łoza B. Jaki lek przeciwdepresyjny dla jakiego pacjenta? Praktyczne wskazówki dla klinicystów. Neuropsychiatria Przegl Klin. 2020;12(3-4):53-59.
Woroń J. Interakcje trójpierścieniowych leków przeciwdepresyjnych. https://www.mp.pl/poz/psychiatria/leki/89037,interakcje-trojpierscieniowych-lekow-przeciwdepresyjnych
Smiley A, Masjedi M, Ani A, et al. New Insights of Anti-Depressant Therapy in the Management of Ulcerative Colitis (UC). Gastroenterology. 2008;134(10.1016/S0016-5085(08)60467-9). doi:10.1016/S0016-5085(08)60467-9
Mikocka-Walus AA, Turnbull DA, Moulding NT, et al. “It doesn’t do any harm, but patients feel better”: a qualitative exploratory study on gastroenterologists’ perspectives on the role of antidepressants in inflammatory bowel disease. BMC Gastroenterol. 2007;7(1):38. doi:10.1186/1471-230X-7-38
Peretti S, Judge R, Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand. 2000;101(S403):17-25. doi:10.1111/j.1600-0447.2000.tb10944.x
Mikocka-Walus AA, Turnbull DA, Moulding NT, et al. Antidepressants and inflammatory bowel disease: a systematic review. Clin Pract Epidemiol Ment Health. 2006;2(1):24. doi:10.1186/1745-0179-2-24
Moreira R. The Efficacy and Tolerability of Bupropion in the Treatment of Major Depressive Disorder. Clin Drug Investig. 2011;31:5-17. doi:10.2165/1159616-S0-000-00000
Brustolim D, Ribeiro-dos-Santos R, Kast RE, et al. A new chapter opens in anti-inflammatory treatments: The antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int Immunopharmacol. 2006;6(6):903-907. doi:10.1016/j.intimp.2005.12.007
Kane S, Altschuler EL, Kast RE. Crohn’s disease remission on bupropion. Gastroenterology. 2003;125(4):1290. doi:10.1016/j.gastro.2003.02.004
Kast RE. Anti- and pro-inflammatory considerations in antidepressant use during medical illness: bupropion lowers and mirtazapine increases circulating tumor necrosis factor-alpha levels. Gen Hosp Psychiatry. 2003;25(6):495-496. doi:10.1016/S0163-8343(03)00093-8
Hashash JG, Knisely MR, Germain A, et al. Brief Behavioral Therapy and Bupropion for Sleep and Fatigue in Young Adults With Crohn’s Disease: An Exploratory Open Trial Study. Clin Gastroenterol Hepatol. 2022;20(1):96-104. doi:10.1016/j.cgh.2020.09.047
Winokur A, Gary KA, Rodner S, et al. Depression, sleep physiology, and antidepressant drugs. Depress Anxiety. 2001;14(1):19-28. doi:10.1002/da.1043
Stuhec M, Munda B, Svab V, Locatelli I. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: A meta-analysis with focus on bupropion. J Affect Disord. 2015;178:149-159. doi:10.1016/j.jad.2015.03.006
Kast RE. Crohn’s disease remission with phenelzine treatment. Gastroenterology. 1998;115(4):1034-1035. doi:10.1016/S0016-5085(98)70292-6
Zhang Z, Zhang WH, Lu YX, et al. Intraoperative Low-Dose S-Ketamine Reduces Depressive Symptoms in Patients with Crohn’s Disease Undergoing Bowel Resection: A Randomized Controlled Trial. J Clin Med. 2023;12(3):1152. doi:10.3390/jcm12031152
Kiraly DD, Horn SR, van Dam NT, et al. Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. Transl Psychiatry. 2017;7(3):e1065-e1065. doi:10.1038/tp.2017.31
Zhou Y, Zheng W, Liu W, et al. Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression. Brain Behav Immun. 2018;74:205-212. doi:10.1016/j.bbi.2018.09.007
Chen LM, Bao CH, Wu Y, et al. Tryptophan-kynurenine metabolism: a link between the gut and brain for depression in inflammatory bowel disease. J Neuroinflammation. 2021;18(1):135. doi:10.1186/s12974-021-02175-2
Getachew B, Aubee JI, Schottenfeld RS, et al. Ketamine interactions with gut-microbiota in rats: relevance to its antidepressant and anti-inflammatory properties. BMC Microbiol. 2018;18(1):222. doi:10.1186/s12866-018-1373-7
Jóźwiak-Bębenista M, Sokołowska P, Wiktorowska-Owczarek A, Kowalczyk E, Sienkiewicz M. Ketamine - A New Antidepressant Drug with Anti-Inflammatory Properties. J Pharmacol Exp Ther. 2024;388(1):134-144. doi:10.1124/jpet.123.001823
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Karol Kasprzak, Agnieszka Dyzma-Kasprzak, Zuzanna Wingralek, Albert Sikorski, Wiktoria Sikorska, Jolanta Wiśniewska, Agnieszka Banaszek, Olga Nowacka
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 242
Number of citations: 0
